You'd think that even NICE would have welcomed with open arms a new, effective treatment option for the UK's nearly 3 million diabet...

There are a few caveats. First, a black box warning for the once-daily GLP-1 analog which includes a potential increased risk of thyroid can...

As the European Commission today gave its final green light to Novo’s much-anticipated GLP-1 inhibitor liraglutide ( Victoza ) (no surprise...

It’s all smiles again at Novo Nordisk following yesterday’s news that EMEA has recommended approval of its GLP-1 agonist liraglutide ( Vict...

Did we—and Novo—speak too soon yesterday about Victoza ’s chances at the FDA advisory committee next month? We reported Novo’s confidence t...